Diquafosol tetrasodium ophthalmic solution, 2%
DrugOne to two drops in each eye QID for 6 weeks
NCT Number: NCT00831662
The purpose of this study is to confirm the safety and efficacy of diquafosol tetrasodium ophthalmic solution, 2% vs. placebo, in subjects with dry eye disease.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One to two drops in each eye QID for 6 weeks
One to two drops in each eye QID for 6 weeks
Time frame: 6 weeks
Time frame: 6 weeks
Merck Sharp & Dohme LLC
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07238699
Dry Eye Disease, Dry Eye Syndromes
Sydney, New South Wales, Australia
View Trial DetailsNCT07025811
Dry Eye Disease, Dry Eye Syndromes
Newport Beach, California, United States
View Trial DetailsNCT07128628
Dry Eye Disease, Dry Eye Syndromes
Phoenix, Arizona, United States
View Trial DetailsNCT07264517
Autoimmune Diseases, Dry Eye Disease
Glendale, California, United States
View Trial Details